Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: A randomized, placebo-controlled trial

American Journal of Medicine

Volumn 101, Issue 4, 1996, Pages 341-348

  Reid, Ian R ^a   Nicholson, Geoffrey C ^b   Weinstein, Robert S ^c   Hosking, David J ^d   Cundy, Tim ^a   Kotowicz, Mark A ^b   Murphy Jr , William A ^e   Yeap, Swan ^d   Dufresne, Suzanne ^f   Lombardi, Antonio ^f   Musliner, Thomas A ^f   Thompson, Desmond E ^f   Yates, A John ^f  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^d NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE;

ADULT; AGED; ARTICLE; BONE MINERALIZATION; BONE PAIN; BONE RADIOGRAPHY; BONE TURNOVER; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORPHOMETRICS; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; OSTEOLYSIS; PAGET BONE DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ALENDRONATE; ALKALINE PHOSPHATASE; BIOPSY; BONE AND BONES; CALCIUM; COLLAGEN; COLLAGEN TYPE I; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEITIS DEFORMANS; PEPTIDES; PHOSPHATES;

EID: 10544223736     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(96)00227-6     Document Type: Article

References (24)

1. 1. Kanis JA. Pathophysiology and Treatment of Paget's Disease of Bone. 1st ed. London: Martin Dunitz; 1991.
2. 2. Cantrill JA, Anderson DC. Treatment of Paget's disease of bone. Clin Endocrinol. 1990; 32:507-518.
3. 3. Kantrowitz FG, Byrne MH, Schiller AL, Krane SM. Clinical and biochemical effects of diphosphonate in Paget's disease of bone. Arthritis Rheum. 1975;18:407.
4. 4. Canfield R, Rosner W, Skinner J, et al. Diphosphonate therapy of Paget's disease of bone. J Clin Endocrinol Metab. 1977;44:96-106.
5. 5. Harinck HIJ, Papapoulos SE, Blanksma HJ, et al. Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD). BMJ. 1987;295:1301-1305.
6. 6. Adami S, Mian M, Gatti P, et al. Effects of two oral doses of alendronate in the treatment of Paget's disease of bone. Bone. 1994;15:415-417.
7. 7. Adami S, Zamberlan N, Mian M, et al. Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of bone, Bone Miner. 1994;25:75-82.
8. 8. O'Doherty DP, Bickerstaff DR, McCloskey EV, et al. Treatment of Paget's disease of bone with aminohydroxybutylidene bisphosphonate. J Bone Miner Res. 1990;5:483-491.
9. 9. Adami S, Salvagno G, Guarrera G, et al. Treatment of Paget's disease of bone with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate. Calcif Tissue Int. 1986;39:226-229.
10. 10. Cleeland CS. Assessment of pain in cancer. Adv Pain Res Ther. 1970;16:47-55.
11. 11. Siris E, Weinstein RS, Altman R, et al. Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. J Clin Endocrinol Metab. 1996;81:961-967.
12. 12. Fenton AJ, Gutteridge DH, Kent GN, et al. Intravenous aminobisphosphonate in Paget's disease: clinical, biochemical, histomorphometric and radiological responses. Clin Endocrinol. 1991;34:197-204.
13. 13. Patel S, Stone MD, Coupland C, Hosking DJ. Determinants of remission of Paget's disease of bone. J Bone Miner Res. 1993;8:1467-1473.
14. 14. Wimalawansa S, Gunaselera RD. Pamidronate is effective for Paget's disease of bone refractory to conventional therapy. Calcif Tissue Int. 1993;53:237-241.
15. 15. Warrell RP, Bosco B, Weinerman S, et al. Gallium nitrate for advanced Paget disease of bone: Effectiveness and dose-response analysis. Ann Intern Med. 1990;113:847-851.
16. 16. Dodd GW, Ibbertson HK, Fraser TRC, et al. Radiological assessment of Paget's disease of bone after treatment with the bisphosphonates EHDP and APD. Brit J Radiol. 1987;60:849-860.
17. 17. Murphy WA, Whyte MP, Haddad JG. Healing of lytic Paget bone disease with diphosphonate therapy. Radiology, 1980; 134:635-637.
18. 18. Doyle FH, Greenberg PB, Joplin GF, MacIntyre I. Radiological evidence of a dose-related response to long-term treatment of Paget's disease with human calcitonin. Brit J Radiol. 1974;47:1-8.
19. 19. Nagant de Deuxchaisnes C, Rombouts-Lindemans C, Haux JP, et al. Roentgenologic evaluation of the efficacy of calcitonin in Paget's disease of bone. In: MacIntyre I, Szelke M, eds. Molecular Endocrinology. 1st ed. Elsevier-North Amsterdam: Elsevier-North Holland Biomedical Press; 1977:213-233.
20. 20. Frijlink WB, te Velde J, Bijvoet OLM, Heynen G. Treatment of Paget's disease with (3-amino-1-hydoxypropylidene)-1,1-bisphosphonate (APD). Lancet. 1979;i:799-803.
21. 21. Meunier PJ, Coindre JM, Edouard CM, Arlot ME. Bone histomorphometry in Paget's disease. Quantitative and dynamic analysis of pagetic and nonpagetic bone tissue. Arthritis Rheum. 1980;23:1095-1103.
22. 22. Eriksen EF, Melsen F, Mosekilde L. Reconstruction of the resorption site in iliac trabecular bone: a kinetic model for bone resorption in 20 normal individuals. Met Bone Dis Rei Res. 1984;5:235-242.
23. 23. Weinstein RS, Bell NB. Diminished rates of bone formation in normal black adults. NEJM. 1988;319:1698-1701.
24. 24. Parfitt AM, Drezner MK, Glorieux FH, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. J Bone Miner Res. 1987;2:595-610.